Losartan Approved In UK For Hypertension
Merck & Co's UK subsidiary Merck Sharp & Dohme has received approval to market its new angiotensin II receptor antagonist, Cozaar (losartan) for the treatment of hypertension in the UK. The product is indicated as a first-line therapy for use in all grades of hypertension and will be launched in February.
The approval comes just a few weeks after MSD filed the application with the UK regulatory authorities, and is the second for the product worldwide. Cozaar was launched in Sweden, its first market, in October 1994. Applications for approval have been filed in most other major markets, including the USA.
The starting dose for Cozaar is one 50mg tablet per day for most patients, although because 55% of the drug is metabolized in the kidney the data sheet recommends that some patients (eg the elderly) should be started on a lower 25mg/day dose. The cost of maintenance therapy is 61 pence (95 cents) a day.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze